Remove BioTech Remove Examples Remove Health Policy
article thumbnail

Prescription Drugs in the Pandemic, Year 2: Pricing Rx and Going Direct-to-Consumer

Health Populi

There is one health care public policy issue that unites U.S. voters across political party: that is the consumer-facing costs of prescription drugs.

article thumbnail

The Healthcare and Macro-Economic Impacts of Living with Endemic COVID – Listening to Fitch

Health Populi

In the larger public and population health context, on the patient side, we can expect the burden of disease beyond COVID to increase due to postponed care and treatment backlogs. for example, for heart disease and cardiovascular complications as well as for cancers. This has been found to be the case in the U.S.,

BioTech 270
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

A Matter of Trust, Perception, Risk, and Uncertainty – The Big Issues Raised by the Acquisition of PatientsLikeMe and Other Patient Data Transactions

Health Populi

When this occurred, it didn’t cause more than a ripple of interest outside biotech. One can probably find examples of and exceptions to that at your local gas station. But the U.S. citizens’ personal data. Sure, there are exceptions to that, but there are exceptions to that at EVERY organization.

article thumbnail

Prescription Drug Costs In America Through the Patient Lens, via IQVIA, GoodRx and a New $2 Million Therapy

Health Populi

In my book, I highlight EpiPen and insulin prices as current examples of patient-consumer uproar, taking the patient-facing costs of these two life-sustaining therapies as quite personal. “A therapy is useless if no one can afford it,” asserted Cathryn Donaldson from AHIP, the health insurance advocacy group, quoted in the story.

Medicare 160